Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.78 |
| ▸ | MAPT | P10636 | 4/20 | 0.78 |
| ▸ | CASP1 | P29466 | 3/20 | 0.78 |
| ▸ | CASP7 | P55210 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 2/20 | 0.78 |
| ▸ | MAOA | P21397 | 2/20 | 0.67 |
| ▸ | XDH | P47989 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.64 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.64 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | IPMK | Q8NFU5 | 2/20 | 0.61 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2629300 | 0.92 | ABCG2 (1.00) | ABCG2KDM4ECYP3A4MAPTCASP1 | |
| SCHEMBL2629309 | 0.89 | ABCG2 (0.84) | ABCG2KDM4ECYP3A4MAPTCASP1 | |
| SCHEMBL38650680 | 0.89 | ABCG2 (0.83) | ABCG2KDM4ECYP3A4MAPTCASP1 | |
| SCHEMBL28536757 | 0.89 | ABCG2 (0.83) | ABCG2KDM4ECYP3A4MAPTCASP1 | |
| SCHEMBL3135319 | 0.88 | KDM4E (1.00) | ABCG2KDM4ECYP3A4MAPTCASP1 | |
| SCHEMBL31412250 | 0.88 | KDM4E (1.00) | ABCG2KDM4ECYP3A4MAPTCASP1 | |
| SCHEMBL4147950 | 0.87 | ABCG2 (0.81) | ABCG2KDM4ECYP3A4MAPTCASP1 | |
| SCHEMBL26936149 | 0.86 | KDM4E (0.82) | ABCG2KDM4ECYP3A4MAPTCASP1 | |
| SCHEMBL30037114 | 0.84 | ADORA3 (0.79) | ABCG2KDM4ECYP3A4MAPTCASP1 | |
| SCHEMBL16894653 | 0.84 | ADORA3 (0.79) | ABCG2KDM4ECYP3A4MAPTCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8137509-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral brønsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-03-20 | — | — | US | disclosed |
| US-7816544-B2 | Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species | TRUSTEES OF BOSTON UNIVERSITY (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| US-20080177093-A1 | Synthesis of Rocaglamide Natural Products Via Photochemical Generation of Oxidopyrylium Species | TRUSTEES OF BOSTON UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | NFKBIA, NFKB1, NFE2L2 | ABCG2 897/4885KDM4E 4342/4885CYP3A4 423/4885 |
| US-20080177093-A1 | Synthesis of Rocaglamide Natural Products Via Photochemical Generation of Oxidopyrylium Species | NFKBIA, NFE2L2, NFKB1 | ABCG2 1928/4885KDM4E 2938/4885CYP3A4 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.